Biofil Chemicals and Pharmaceuticals Ltd Announces Q3 FY26 Financial Results

Biofil Chemicals and Pharmaceuticals Ltd has announced its unaudited financial results for the third quarter ended December 31, 2025, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were digitally signed and released on February 14, 2026. Financial Performance Overview The company's financial performance for Q3 FY26 showed mixed results compared to the previous year. The detailed financial metrics demonstrate the company's operational performance during the quarter. Particulars Q3 FY26 (Dec 31, 2025) Q3 FY25 (Dec 31, 2024) FY25 (Mar 31, 2025) Total Income from Operations (Net) Rs. 93.46 lakhs Rs. 1421.82 lakhs Rs. 3370.74 lakhs Net Profit Before Tax Rs. 10.67 lakhs Rs. 22.16 lakhs Rs. 73.61 lakhs Net Profit After Tax Rs. 7.92 lakhs Rs. 16.46 lakhs Rs. 55.78 lakhs Total Comprehensive Income Rs. 7.92 lakhs Rs. 16.46 lakhs Rs. 57.87 lakhs Key Financial Metrics The company maintained its equity share capital at Rs. 1627.38 lakhs across all reported periods. Earnings per share metrics for the quarter showed consistent performance between basic and diluted calculations. Financial Metric Q3 FY26 Q3 FY25 FY25 Equity Share Capital Rs. 1627.38 lakhs Rs. 1627.38 lakhs Rs. 1627.38 lakhs Basic EPS (Rs. 10/- each) Rs. 0.05 Rs. 0.10 Rs. 0.34 Diluted EPS (Rs. 10/- each) Rs. 0.05 Rs. 0.10 Rs. 0.34 Regulatory Compliance and Disclosure The financial results were prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 as amended. The complete format of the unaudited financial results has been filed with stock exchanges and is available on the company's website at www.biofilgroup.net , as well as on BSE ( www.bseindia.com ) and NSE ( www.nseindia.com ) websites. Company Information Biofil Chemicals and Pharmaceuticals Ltd operates under CIN: L24233MP1985PLC002709 with its registered office located at B/12-B, Industrial Estate, Pologround, Indore-452015 (M.P.) India. The results were signed by Ketan Shah, Chairman & Managing Director (DIN: 08818212), and released from Indore on February 13, 2026. The company has also provided a Quick Response (QR) code for easy access to the detailed financial results, enabling stakeholders to quickly retrieve comprehensive financial information. Source: Shree Pacetronix Limited has received formal trading approval from BSE Limited for 75,150 equity shares issued to promoters on a preferential basis. The approval, effective from January 22, 2026, marks a significant corporate development for the cardiac pacing technology company. Share Issuance Details The approved equity shares carry specific financial and technical parameters that define the preferential allotment structure. Parameter: Details Number of Shares: 75,150 equity shares Face Value: ₹10.00 per share Premium: ₹71.00 per share Issue Price: ₹81.00 per share Distinctive Numbers: 3599401 to 3674550 Allottee: Promoter The total value of the preferential allotment amounts to ₹60.87 crores, calculated at the issue price of ₹81.00 per share. This represents a premium of 710% over the face value, indicating strong confidence in the company's prospects. Regulatory Compliance and Approval Process The trading approval was granted under strict regulatory compliance with SEBI Listing Regulations. BSE Limited issued the approval letter on January 21, 2026, with reference number LOD/PREF/PB/249/2025-2026. The exchange confirmed that the securities are listed effective from January 22, 2026. Shree Pacetronix Limited has fulfilled all necessary regulatory requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company's compliance was overseen by Company Secretary Rupali Ahire, who digitally signed the regulatory intimation. Company Background and Operations Shree Pacetronix Limited operates as a specialized medical technology company focusing on cardiac pacing solutions. The company is currently celebrating 25 years of operations in the cardiac pacing industry, demonstrating its established presence in the healthcare technology sector. Corporate Details: Information CIN: L33112MP1988PLC004317 Scrip Code: 527005 ISIN: INE847D01010 Industry Focus: Cardiac Pacing Technology Years of Operation: 25 years The company maintains multiple operational locations across India, including its registered office and factory in Pithampur, Madhya Pradesh, along with offices in Bangalore and Kolkata. Shree Pacetronix Limited holds several quality certifications including ISO 13485 and ISO 9001, reflecting its commitment to medical device manufacturing standards. Market Implications The successful completion of the preferential allotment process and receipt of trading approval demonstrates the company's ability to execute capital raising initiatives effectively. The preferential shares are now available for trading on BSE Limited, providing liquidity options for the promoter while maintaining compliance with all regulatory requirements. BSE Limited has issued Notice No. 20260121-20 dated January 21, 2026, to inform trading members about the listing of these securities. This formal notification ensures market participants are aware of the new shares available for trading. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.